Anti proliferative activity of ELACYT™ (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells

David J. Adams Department of Medicine, Duke University Medical Center, Durham, NC, USACorrespondence[email protected]

Marit L. Sandvold Preclinical, Chemical and Pharmaceutical Research and Development, Clavis Pharma ASA, NO-0256, Oslo, Norway

Finn Myhren Preclinical, Chemical and Pharmaceutical Research and Development, Clavis Pharma ASA, NO-0256, Oslo, Norway

Tove F. Jacobsen Preclinical, Chemical and Pharmaceutical Research and Development, Clavis Pharma ASA, NO-0256, Oslo, Norway

Frank Giles University of Texas Health Science Center, San Antonio, TX, USA

David A. Rizzieri Department of Medicine, Duke University Medical Center, Durham, NC, USA

Your download is now in progress and you may close this window